Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is a clinical-stage biotechnology company with a strong focus on improving outcomes for cancer patients, particularly in the areas of breast and endometrial cancer. The company's leading drug candidate, Piktor, has shown promising results in preclinical and early clinical studies and has initiated coverage with a Buy rating and a $70 price target. Ongoing trials and the potential for improving tolerability and efficacy suggest potential for continued success.

Bears say

Faeth Therapeutics is facing several key challenges in the development and potential success of their drug PIKTOR. These challenges include finding a tolerable dosage, competition from other drugs, and the risks associated with a single-arm Phase 2 design. Additionally, the estimated equity value for the company is quite high, which may not be sustainable if the drug does not meet expectations or faces major setbacks in its development.

FTH has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Strong Buy based on their latest research and market trends.

According to 10 analysts, FTH has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.